Somatropin

Pediatric Patients: Omnitrope injection is used to treat pediatric patients whose growth failure results from an inadequate supply of the body's own growth hormone (GH). It is also used to treat pediatric patients with short stature linked to Noonan syndrome, short stature linked to Turner syndrome, and short stature in children born small for gestational age (SGA) who have not shown catch-up growth by 2 to 4 years of age. Adult Patients: In adults, Omnitrope injection is used to replace the body's own GH in those with growth hormone deficiency (GHD) who meet one of two criteria. The first is Adult Onset (AO), covering patients whose GHD, whether occurring on its own or together with multiple hormone deficiencies (hypopituitarism), stems from pituitary disease, hypothalamic disease, surgery, radiation therapy, or trauma. The second is Childhood-Onset (CO), covering patients who were GH deficient as children for congenital, genetic, acquired, or idiopathic reasons. Patients who received Omnitrope for GHD in childhood and whose epiphyses have since closed should be reassessed before continuing therapy, at the lower dose recommended for adults with GHD. Under current standards, confirming adult GHD in both groups calls for an appropriate growth hormone provocative test, with two exceptions: (1) patients who have multiple other pituitary hormone deficiencies caused by organic disease, and (2) patients with congenital or genetic growth hormone deficiency.